About this trial
This study looks at how well tebentafusp works in treating advanced melanoma. Participants will receive either tebentafusp alone, tebentafusp with another drug called pembrolizumab, or the doctor's choice of treatment. The goal is to see which option is more effective and safe for patients who have already received other treatments.
This is a Phase 3 trial, meaning it is looking at how well the treatment works and how safe it is. The trial hopes to include around 540 participants and is regulated by the FDA.
Who can join
Adults aged 18 and older can join this trial. It is open to men and women who have a specific type of melanoma that can't be removed by surgery. Participants must be able to provide tumor samples and meet other health criteria. The trial team will confirm who is eligible to participate.
Condition
Advanced Melanoma
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will be placed into one of three groups by chance. - Arm A will receive tebentafusp alone. - Arm B will receive tebentafusp along with pembrolizumab. - Arm C will receive the treatment chosen by their doctor. Everyone will be monitored for their health during the study.
Where
This trial is running at 25 locations in the United States. All of them are currently recruiting.
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Fred Hutchinson Cancer Center
Seattle, Washington
Gibbs Cancer Center and Research Institute
Spartanburg, South Carolina
Houston Methodist Hospital/Houston Methodist Cancer Center
Houston, Texas
Massachusetts General Hospital
Boston, Massachusetts
Mayo Clinic Arizona
Phoenix, Arizona
Mayo Clinic Florida
Jacksonville, Florida
The first 8 of 25 sites are listed here. The registry record has the full list.